Rafael Parra Medina’s Post

Latest publication on the CryoBalloon for Squamous Cancer (NonUS) now available in GIE. Results: October 2020 to October 2021, 15 patients with 17 lesions underwent cryoablation, with two requiring repeat cryoablation. The L-CR rate for primary and all lesions evaluated by the central evaluation committee was 100%. The endoscopist’s evaluation was consistent with these results. The median procedure time was 9 min. Eight patients experienced no pain, and the highest pain score reported on a numeric 1-10 rating scale was 3.  #endoscopy #UEGW #cryo

Transitional Cell Carcinoma Illustration showing the enhancement of transitional cell carcinoma across the 4 phases of CT. https://lnkd.in/eui6ynYx

Latest ESMO Open podcast now online 👉 Maria Kfoury & David Tan discuss developments in research in the systemic therapy of ovarian clear cell carcinoma: Are there any specific issues, and should they be treated separately? https://ow.ly/FU5M50QxVgp #OvarianCancer

Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/jbM5hq

Cohort study aims to establish whether anterior vs posterior tumor extension may represent a prognostic factor in oral tongue and floor squamous cell carcinoma. https://ja.ma/3ODk2Q9

Clinical response of T3 squamous cell carcinoma of the tongue, treated with neoadjuvant pembrolizumab-carboplatin-paclitaxel. Significant reduction of the tumor size.

Gain valuable insights into how collaboration among different healthcare professionals can lead to early detection and better outcomes for patients with advanced cases of basal cell carcinoma (BCC) and advanced cutaneous squamous cell carcinoma (CSCC). Register here: https://okt.to/RpId8e

The neoadjuvant combination of camrelizumab, nab-paclitaxel & cisplatin demonstrated statistically significant enhancements in pCRs compared with solitary chemotherapy in resectable locally advanced esophageal squamous cell carcinoma. https://lnkd.in/ei3axH2q

𝙀𝙛𝙛𝙞𝙘𝙖𝙘𝙮 𝙖𝙣𝙙 𝙩𝙤𝙭𝙞𝙘𝙞𝙩𝙮 𝙤𝙛 𝙖𝙣𝙡𝙤𝙩𝙞𝙣𝙞𝙗 𝙥𝙡𝙪𝙨 𝙘𝙖𝙢𝙧𝙚𝙡𝙞𝙯𝙪𝙢𝙖𝙗 𝙫𝙚𝙧𝙨𝙪𝙨 𝙖𝙣𝙡𝙤𝙩𝙞𝙣𝙞𝙗 𝙥𝙡𝙪𝙨 𝙎-1 𝙖𝙨 𝙨𝙚𝙘𝙤𝙣𝙙-𝙡𝙞𝙣𝙚 𝙩𝙝𝙚𝙧𝙖𝙥𝙮 𝙛𝙤𝙧 𝙖𝙙𝙫𝙖𝙣𝙘𝙚𝙙 𝙚𝙨𝙤𝙥𝙝𝙖𝙜𝙚𝙖𝙡 𝙨𝙦𝙪𝙖𝙢𝙤𝙪𝙨 𝙘𝙚𝙡𝙡 𝙘𝙖𝙧𝙘𝙞𝙣𝙤𝙢𝙖: 𝘼 𝙧𝙚𝙖𝙡-𝙬𝙤𝙧𝙡𝙙 𝙧𝙚𝙩𝙧𝙤𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚 𝙨𝙩𝙪𝙙𝙮. A recent study explores #anlotinib plus #camrelizumab as a #secondlinetherapy for advanced #esophagealsquamouscell #carcinoma. Promising results show longer #survival time, improved #diseasecontrol, and manageable #sideeffects.  Read more here:  https://lnkd.in/gVBZT7KW

Another proof of the urgent need of implementing liquid biopsy in the management of digestive cancers